<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127515</url>
  </required_header>
  <id_info>
    <org_study_id>P130601</org_study_id>
    <secondary_id>2013-A00998-37</secondary_id>
    <nct_id>NCT02127515</nct_id>
  </id_info>
  <brief_title>Non Invasive Prenatal Testing of Down Syndrome</brief_title>
  <acronym>SAFE 21</acronym>
  <official_title>Non Invasive Prenatal Testing of Down Syndrome From Maternal Blood Sample</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial in women at risk following combined prenatal screening&#xD;
      for Down Syndrome. Women will be asked about their preferences between NIPT and routine&#xD;
      prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between&#xD;
      NIPT and standard invasive prenatal diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial in women at risk following combined prenatal screening&#xD;
      for Down Syndrome. Women will be asked about their preferences between NIPT and routine&#xD;
      prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between&#xD;
      NIPT and standard invasive prenatal diagnosis.&#xD;
&#xD;
      The general objectives are :&#xD;
&#xD;
        -  Promote the rapid and large implementation of Non Invasive Prenatal Testing (NIPT) for&#xD;
           Down syndrome.&#xD;
&#xD;
        -  Improve the management of women at risk after combined first trimester screening and&#xD;
           reduce the number of invasive procedures and induced miscarriages .&#xD;
&#xD;
        -  Evaluate NIPT medically (in reducing the rate of invasive sampling and related&#xD;
           complications, diagnostic performance and feasibility and acceptability in routine&#xD;
           practice) and based on cost-analysis in comparison with standard invasive prenatal&#xD;
           diagnosis currently proposed .&#xD;
&#xD;
        -  Clarify the conditions of implementation and dissemination of NIPT in the overall&#xD;
           organization of prenatal screening for trisomy 21 (and provide data to later adjust or&#xD;
           not the combination of tests and thresholds).&#xD;
&#xD;
      Promote the organization as networks of professionals involved in prenatal screening for&#xD;
      trisomy 21 in order to allow the emergence of a national system of collection of outcomes to&#xD;
      improve the quality of practices&#xD;
&#xD;
      The main judgement criteria are:&#xD;
&#xD;
        -  Main:&#xD;
&#xD;
           - Percentage of fetal loss in each group&#xD;
&#xD;
        -  Secondary:&#xD;
&#xD;
             -  Percentage of invasive tests in each group (amniocentesis or chorionic villus&#xD;
                sampling )&#xD;
&#xD;
             -  Diagnostic performance of NIPT , in particular false positive and negative&#xD;
&#xD;
             -  Percentage of results within 3 weeks and average time interval for results of NIPT&#xD;
&#xD;
             -  Percentage of inconclusive results of DPANI&#xD;
&#xD;
             -  Percentage of other anomalies discovered at invasive sampling&#xD;
&#xD;
             -  Percentage of invasive samples taken despite normal NIPT (either because of later&#xD;
                ultrasound anomaly or for maternal reinsurance)&#xD;
&#xD;
             -  Association between maternal characteristics ( weight, height, parity , previous&#xD;
                history , serum markers ... ) and the results of NIPT&#xD;
&#xD;
             -  Cost analysis of NIPT in routine clinical practice&#xD;
&#xD;
      The study will include 2450 high risk women in order to be powered enough to detect a 1%&#xD;
      reduction of miscarriages in the group undergoing NIPT instead of routine invasive prenatal&#xD;
      diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2014</start_date>
  <completion_date type="Actual">November 7, 2016</completion_date>
  <primary_completion_date type="Actual">November 7, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number or miscarriages</measure>
    <time_frame>at birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number or invasive tests</measure>
    <time_frame>at birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>false positive and negative rates of NIPT</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dedicated questionnaire for patients</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of invasive tests and NIPT in euros</measure>
    <time_frame>at birth</time_frame>
    <description>measure in euros</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2111</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>Non Invasive Prenatal Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive Prenatal Testing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVS or amniocentesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non Invasive Prenatal Testing</intervention_name>
    <arm_group_label>Non Invasive Prenatal Testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive Prenatal Testing</intervention_name>
    <arm_group_label>Invasive Prenatal Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women over 18&#xD;
&#xD;
          -  at risk for Down syndrome&gt; 1/250 based on combined screening using ultrasound together&#xD;
             with maternal serum markers and prior to fetal karyotyping&#xD;
&#xD;
          -  singleton pregnancy&#xD;
&#xD;
          -  pregnancy between 11SA et 18SA&#xD;
&#xD;
          -  willing a fetal karyotype&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  risk for Down syndrome&lt; 1/250 or &gt;1/5&#xD;
&#xD;
          -  NT&gt; 3 mm, PAPP-A or beta HCG &lt;0.3 MoM or &gt;5 MoM&#xD;
&#xD;
          -  multiple pregnancy , vanishing twin&#xD;
&#xD;
          -  morphological abnormalities at US&#xD;
&#xD;
          -  Kown chromosomal anomaly in parents&#xD;
&#xD;
          -  Patients not willing a fetal karyotype&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent J Salomon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel VEKEMANS, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker- Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Down, trisomy 21</keyword>
  <keyword>NIPT</keyword>
  <keyword>Amniocentesis</keyword>
  <keyword>miscarriage</keyword>
  <keyword>invasive</keyword>
  <keyword>prenatal</keyword>
  <keyword>screening.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

